Clinical Trials

Phase 3 Active not recruiting

Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT05771480 2026-03-25

TOURMALINE

142 enrolled

Phase 3 Active not recruiting

Biliary Tract Neoplasms

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

757 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

387 enrolled

Neoplasms, Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 7 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03013010 2025-12-08

PREACT

204 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT05593458 2025-04-09

TACTIC

190 enrolled

Stomach Neoplasms

NCT02867839 2024-12-03

RESCUE-GC

Phase 3 Terminated

29 enrolled

Stomach Neoplasms

NCT01285557 2024-09-19

DIGEST

Phase 3 Terminated

361 enrolled 18 charts

Phase 3 Active not recruiting

Stomach Neoplasms

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

626 enrolled

Phase 3 Not yet recruiting

Stomach Neoplasms

NCT06571461 2024-08-27

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

408 enrolled

Pancreatic Neoplasms

NCT06194734 2024-03-07

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

490 enrolled

Esophageal Squamous Cell Carcinoma

NCT01515748 2023-12-13

PRODIGY

530 enrolled 11 charts

Stomach Neoplasms

NCT02338518 2023-09-29

SVOSA

297 enrolled

Stomach Neoplasms

NCT05813015 2023-04-14

Study of Comparing of With and Without Sequential Therapy of S-1

70 enrolled

Locally Advanced Gastric Adenocarcinoma

NCT03801668 2022-01-04

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

294 enrolled

Stomach Neoplasms

NCT03961867 2021-06-01

Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma

440 enrolled

Stomach Neoplasms

NCT02114359 2020-10-23

Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer

111 enrolled

Stomach Neoplasms

NCT02813967 2020-09-16

S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer

298 enrolled

Phase 3 Not yet recruiting

Esophageal Neoplasms

NCT04465968 2020-07-10

DEEP_OCEAN

84 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Pancoast Syndrome

NCT04135781 2020-03-23

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

616 enrolled

Stomach Neoplasms

NCT00915382 2020-01-07

Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS

625 enrolled

Advanced Gastric Cancer

NCT00770874 2019-06-21

Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

375 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms

NCT03941561 2019-05-31

S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）

1,006 enrolled

Stomach Neoplasms

NCT02736552 2019-05-08

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Phase 3 Withdrawn

Stomach Neoplasms

NCT02182778 2019-02-21

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

246 enrolled

Biliary Tract Neoplasms

NCT01824459 2019-01-23

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

576 enrolled

Stomach Neoplasms

NCT03475615 2018-03-23

A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites

215 enrolled

Stomach Neoplasms

NCT01918852 2018-03-14

SALTO

161 enrolled

Neoplasm Metastasis, Colorectal Neoplasms, Hand-Foot Syndrome

NCT03061058 2017-09-15

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

240 enrolled

Stomach Neoplasms

NCT01795027 2016-10-25

CAPITAL

724 enrolled

Stomach Neoplasms

NCT00660894 2016-08-03

Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

1,535 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT00602745 2016-05-26

S-1 Pancreas

Phase 3 Terminated

61 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02677597 2016-02-09

Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

268 enrolled

Esophageal Squamous Cell Carcinoma

NCT01671449 2015-11-30

SOPP

338 enrolled

Stomach Neoplasms

NCT02319187 2015-08-03

Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial

240 enrolled

Esophageal Neoplasms

NCT00677443 2013-06-14

Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

344 enrolled

Colorectal Neoplasms

NCT01283217 2013-06-04

Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer

166 enrolled

Gastric Adenocarcinoma

NCT00152217 2011-07-07

Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)

1,000 enrolled

Stomach Neoplasms

NCT00202969 2011-07-07

Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer

180 enrolled

Stomach Neoplasms

NCT00287768 2011-06-28

Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer

628 enrolled

Stomach Neoplasms

NCT00316745 2007-11-01

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Phase 3 Suspended

200 enrolled